BIOSCRUB (chlorhexidine gluconate) by Johnson & Johnson is clinical pharmacology periogard® (chlorhexidine gluconate oral rinse usp, 0. Approved for surgical site infection, staphylococcus aureus infection. First approved in 1989.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
BIOSCRUB is a topical chlorhexidine gluconate sponge formulation approved in 1989 for surgical site infection and Staphylococcus aureus infection prevention. The drug works through broad-spectrum antimicrobial activity, reducing aerobic and anaerobic bacteria counts by 54-97% with approximately 30% oral cavity retention and slow release into oral fluids. Poor systemic absorption (peak plasma level 0.206 µg/g) limits drug-drug interactions and systemic toxicity.
As a 35-year-old product approaching loss of exclusivity with 30% competitive pressure, the BIOSCRUB brand team likely faces contraction, favoring transition-focused roles in cost optimization and generic transition planning.
CLINICAL PHARMACOLOGY PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general…
Worked on BIOSCRUB at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
BIOSCRUB offers limited career growth as a legacy topical antiseptic in LOE-approaching stage with zero linked job openings. Roles on this brand typically focus on market defense, generic transition planning, and cost optimization rather than innovation or launch dynamics.